去势抵抗性前列腺癌分子信号通路的研究进展  

Research progress on the molecular signaling pathway of castration-resistant prostate cancer

作　　者：张秀娜[1] 赵伟[1] 高晓芳[1] 杨勇[2] 季晖[1] 

机构地区：[1]中国药科大学药学院,江苏南京211198 [2]中国药科大学药物研究院,江苏南京211198

出　　处：《药学研究》2015年第4期225-228,共4页Journal of Pharmaceutical Research

基　　金：国家自然科学基金(No.81272097)

摘　　要：在美国前列腺癌(PCa)是男性最常见的非皮肤性癌症以及癌症相关死亡的第二号杀手。雄激素与雄激素受体是前列腺癌的关键效应器,因此,雄激素剥夺治疗(ADT)是前列腺癌患者的一线治疗方法,并且效果良好,但是前列腺肿瘤最终复发并进展为去势抵抗性前列腺癌(CRPC)这一致命性形式。研究雄激素受体与去势抵抗性前列腺癌发生发展的关系及其可能的分子机制,可以为其临床诊断、治疗以及进一步的研究提供科学依据。In United States,prostate cancer is the most commonly diagnosed non-cutaneous cancer in males and the second leading cause of cancer-related death for men. Androgen and the androgen receptor（ AR）are critical effectors of prostate cancer. Consequently,androgen deprivation therapy（ ADT）is typically employed as a first-line treatment for pros-tate cancer patients. While initial responses are generally positive,prostate tumors frequently recur and progress to a lethal form known as castration-resistant prostate cancer（ CRPC）. To study the relationship between androgen receptor and the initiation and development of CRPC,along with the possible molecular mechanisms,helps to diagnosis and treatment of cas-tration-resistant prostate cancer（ CRPC）,and provide the basis for further research.

关 键 词：去势抵抗性前列腺癌 雄激素受体 信号转导 分子机制 

分 类 号：R730.5[医药卫生—肿瘤]